Market News

Cramer Shares Insight on Major Healthcare Stock and More Cramer Shares Insight on Major Healthcare Stock and More

Jim Cramer’s Take on Healthcare Stocks

On CNBC’s “Mad Money Lightning Round,” Jim Cramer shared his insights on various stocks. When asked about ImmunoGen, Inc., he noted that it is now a property of AbbVie and swiftly moved on. Cramer expressed his reluctance to invest in Ramaco Resources, Inc., emphasizing a wait-and-see approach. Referring to Bitfarms Ltd., Cramer labeled it as a speculative venture, indicating caution. He also expressed his outlook on Micron Technology, Inc., projecting potential for the stock to remain steady or rise.

Cramer voiced his views on specific companies, describing Coherent Corp. as “a little too expensive” and asserting that GE HealthCare Technologies Inc. is “ridiculously cheap” and is “doing so many great things.” In relation to TKO Group Holdings, Inc., he admitted that he struggled to evaluate the company. Moreover, he recommended Arm Holdings plc as a stock worth owning, commending the performance of its CEO, Rene Haas. Cramer also cited an upcoming earnings report for the chipmaker, scheduled for November 8.

Additionally, Cramer expressed his disinterest in Teva Pharmaceutical Industries Limited.

Price Movement

Following the recent discussion, shares of various companies experienced price movements. Teva’s stock gained 4.1%, Arm Holdings saw a 2% decline, and TKO Group Holdings fell by 0.3%. Meanwhile, GE HealthCare’s stock rose by 0.1% and Coherent shares experienced a 1.4% increase. Micron Technology also fared positively with a rise of 0.9%. Bitfarms shares faced a 7.2% decrease, whereas Ramaco Resource’s stock dipped by 1.2%. ImmunoGen observed a 0.4% gain, and AbbVie shares also increased by 0.4%. Finally, Realty Income ended with a 0.4% rise during the session.

See also  Intel Corporation's Stock Struggles Amidst Earnings Woes The Downfall of Intel's Stock Post-Earnings Revelation

Intel Corporation (INTC), known for its stronghold in the semiconductor industry, recently unveiled a challenging second quarter that has left analysts and investors apprehensive about the company's future performance. The disappointing earnings report, marked by revenue declines, substantial job cuts, and the suspension of dividends, has triggered a cascade of lowered price targets and downgrades, casting a somber shadow over Intel's once-sturdy stock standing.

Insight into Intel's Stock

Based in Santa Clara, California, Intel Corporation (INTC) commands a market capitalization of $80.84 billion within the global semiconductor domain. Specializing in the production of an array of computing products like microprocessors, chipsets, and cutting-edge driver assistance systems for autonomous vehicles, Intel has seen a plummet of 62.2% in its year-to-date stock performance, vastly underperforming the general market.

www.barchart.com The Abrupt Plummet of Intel's Shares Post-Q2 Reveal

Following the recent investor call on August 1, Intel reported lower-than-anticipated Q2 results, issuing a lackluster Q3 forecast. Additionally, the tech giant revealed plans for a sizable reduction in its workforce by over 15% and the halting of dividend payments. Subsequently, Intel's shares nosedived by over 26% in the subsequent trading period.

In Q2, Intel recorded total revenue of $12.8 billion, a slight 1% drop compared to the previous year, missing estimates by $150 million. While the company witnessed a 4% revenue growth in its Products unit, led by robust client computing gains offsetting modest declines in the data center segment, it failed to match the soaring growth experienced by its competitors in this domain.

With the revenue dip year-over-year, the non-GAAP gross margin fell as well, dropping 1.1 percentage points to 38.7%, notably beneath the company's anticipated 43.5% mark. This decline, coupled with a 5% increase in operational expenses, saw the adjusted operating margin shrink to a mere 0.2%, a significant regression from the 3.5% reported in the prior year.

Challenges Ahead: Lunar Lake's Looming Margins and Margin-Recovery Strategies

Intel's woes deepen with the impending release of its Lunar Lake CPU in late Q3, a product lineup that is slated to face margin constraints. The limited adoption of Lunar Lake, influenced by its release timing, poses a significant obstacle to Intel's profit margins, necessitating the company to postpone its 60% margin target until 2026.

On a more hopeful note, Intel is counting on its forthcoming 18A process products, like Panther Lake and Clearwater Forest, due to launch in the latter half of 2025, to revamp its profit margins. However, the benefits from these new products and processes are not expected to materialize until 2026.

Marked by revenue and margin hurdles alongside substantial capital expenses and a hefty $48 billion debt load, Intel has embarked on an aggressive cost-reduction initiative. This involves a 15% slash in its 110,000-strong workforce, a more than 20% decrease in projected 2024 investments in new infrastructure, with spending now ranging between $25 billion and $27 billion.

Intel Faces Investor BacklashIntel's Dive into the Abyss: Investor Backlash After Dividend Suspension

Cramer’s commentary on these healthcare stocks and more offers unique perspectives for investors, highlighting aspects such as value, speculation, and growth potential within the sector.